The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The Midwest CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the Midwest CEPAC process, and Find out how topics are selected.
Midwest CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the Midwest CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the Midwest CEPAC. For more information about past and other upcoming meetings, see the box to the right.
University of Chicago Gleacher Center at the Booth School of Business
450 N Cityfront Plaza Drive
Chicago, IL 60611
Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults in the US. Management of atopic dermatitis can create burdens for the family, and the disorder can decrease quality of life. Itching, in particular, can disrupt sleep and lead to daytime sleepiness, irritability, and psychological stress, and cosmetically important lesions can lead to social stress and isolation.
ICER’s report will evaluate the comparative clinical effectiveness and value of two emerging therapies for atopic dermatitis: crisaborole and dupilumab. Crisaborole will be evaluated based on its expected indication in the treatment of mild-to-moderate atopic dermatitis in children and adults; separately, dupilumab will be evaluated for its expected indication in the treatment of moderate-to-severe atopic dermatitis in adults.
Interventions of Interest:
- Crisaborole (Eucrisa™, Pfizer, Inc.)
- Dupilumab (Dupixent®, Sanofi and Regeneron, Inc.)
Date of Review: May 2017View materials